// App-Quantinova.ai

TPS9608 : SWOG S1512: A phase II and pilot trial of pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM).

Researchers

Presenter

  • Kari Lynn Kendra

Principal Investigators

  • James Moon

  • Siwen Hu-Lieskovan

  • William Edgar Carson

  • Danae Campos

  • Alistair Cochran

  • Michael Wu

  • Antoni Ribas

Medical Centers

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Southwest Oncology Group Statistical Center, Seattle, WA

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • The Ohio State University Comprehensive Cancer Center, Department of Surgery, Columbus, OH

  • SWOG Operatons Office, San Antonio, TX

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • SWOG Statistical Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • T-cell receptor

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • II

Study Id's

  • NCT02775851

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved